Select Page

News

Exciting breakthroughs in RNA Therapeutics for Progeria!

Exciting breakthroughs in RNA Therapeutics for Progeria!

We’re thrilled to share the results from two very exciting breakthrough studies on the use of RNA therapeutics in Progeria research. Both studies were co-funded by The Progeria Research Foundation (PRF) and co-authored by PRF’s Medical Director, Dr. Leslie Gordon.

read more
Kicking off the New Year with exciting research news!

Kicking off the New Year with exciting research news!

In January, the science journal Nature published breakthrough results demonstrating that genetic editing in a mouse model of Progeria corrected the mutation that causes Progeria in many cells, improved several key disease symptoms and dramatically increased lifespan in the mice.

read more
Hot off the Presses: PRF’s 2020 Newsletter!

Hot off the Presses: PRF’s 2020 Newsletter!

Read about how our progress continues despite the pandemic; the science driving PRF’s latest grant recipients to propel Progeria research to new heights; inspiring thoughts from families in our Progeria community; and so much more.

read more
July 20: PRF’s Annual ONEpossible Campaign a Success!

July 20: PRF’s Annual ONEpossible Campaign a Success!

From all of us at PRF, as well as the children and their families, THANK YOU to everyone who donated to our ONEpossible campaign!!
We CRUSHED our goal – which will help to offset funds lost from cancelled events due to COVID-19 – and couldn’t have done it without your support!

read more
A Note to our PRF Community

A Note to our PRF Community

First and foremost, we hope you are staying well. In light of the recent progression of COVID-19, and as we all navigate this uncertain time, we want to THANK YOU for your support and let you know that our fight against Progeria remains steadfast.

read more
Application to FDA for lonafarnib approval is COMPLETE!

Application to FDA for lonafarnib approval is COMPLETE!

During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval – in Europe and the US – of the drug lonafarnib as a first-ever treatment for Progeria.

read more